Role of Uremic Toxins and Oxidative Stress in the Development of Chronic Kidney Disease-Mineral and Bone Disorder

Journal of Renal Nutrition

Volumn 22, Issue 1, 2012, Pages 98-101

  Tanaka, Hisae ^a   Komaba, Hirotaka ^a   Koizumi, Masahiro ^a   Kakuta, Takatoshi ^a   Fukagawa, Masafumi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CHELATING AGENT; DRUG DERIVATIVE; LYSINE; MINERAL; PARATHYROID HORMONE; PENTOSIDINE; POLYAMINE; SEVELAMER;

ARTICLE; BLOOD; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CHRONIC KIDNEY FAILURE; HOMEOSTASIS; HYPERPARATHYROIDISM; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; UREMIA;

ARGININE; BONE DISEASES; CHELATING AGENTS; HOMEOSTASIS; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; LYSINE; MINERALS; OXIDATIVE STRESS; PARATHYROID HORMONE; POLYAMINES; RENAL DIALYSIS; UREMIA; VASCULAR CALCIFICATION;

EID: 84855165950     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.10.031     Document Type: Article

References (22)

1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009, 113:S1-S130. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group.
2. Fukagawa M., Komaba H., Ohnishi Y., Fukuhara S., Akizawa T., Kurokawa K. Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D. Am J Nephrol 2011, 33:427-437. MBD5D study group.
3. Fukagawa M., Kazama J.J., Shigematsu T. Skeletal resistance to PTH as a basic abnormality underlying uremic bone disease. Am J Kidney Dis 2001, 38(4 suppl. 1):S152-S155.
4. Iwasaki-Ishizuka Y., Yamato H., Nii-Kono T., et al. Down-regulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of chronic renal failure with low turnover bone. Nephrol Dial Transplant 2005, 20:1904-1911.
5. Iwasaki Y., Yamato H., Nii-Kono T., et al. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant 2006, 21:2768-2774.
6. Nii-Kono T., Iwasaki Y., Yamato H., Fukagawa M. Indoxyl sulfate induced skeletal resistance to PTH in osteoblastic cells. Kidney Int 2007, 71:738-743.
7. Goto S., Hamada Y., Yoshiya K., Fukagawa M. Indoxyl sulfate is associated with skeletal resistance to parathyroid hormone in dialysis patients. Ther Apher Dial 2010, 14:417-423.
8. Muteliefu G., Enomoto A., Jiang P., Takahashi M., Niwa T. Indoxyl sulfate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. Nephrol Dial Transplant 2009, 24:2051-2058.
9. Barreto F.C., Barreto D.V., Llabeuf S., et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009, 4:155-158.
10. Abe T., Shono M., Kodama T., Kita Y., Fukagawa M., Akizawa T. Extracorporeal albumin dialysis. Ther Apher Dial 2005, 8:217-222.
11. Goto S., Yoshiya K., Kita T., Fujii H., Fukagawa M. Uremic toxins and oral adsorbents. Ther Apher Dial 2011, 15:132-134.
12. Miyamoto Y., Iwao Y., Tasaki Y., et al. The uremic solute indoxyl sulfate acts as an antioxidant against superoxide anion radicals under normal-physiological conditions. FEBS Letters 2010, 584:2816-2820.
13. Hamada Y., Fujii H., Fukagawa M. The role of oxidative stress in diabetic bone disorders. Bone 2009, 45:S35-S38.
14. Tanaka M., Tokunaga K., Komaba H., et al. Vitamin D receptor activator reduces oxidative stress in hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 2011, 15:161-168.
15. Shoji T., Shinohara K., Kimoto E., et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in hemodialysis population. Nephrol Dial Transplant 2004, 19:179-184.
16. Block G.A., Zaun D., Smits G., et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010, 78:578-589.
17. Tanaka M., Tokunaga K., Maruyama T., et al. Parathyroidectomy markedly reduce oxidative stress in a patient with primary hyperparathyroidism. Ther Apher Dial 2011, 15(suppl 1):38-41.
18. Iwasaki Y., Yamato H., Fukagawa M. Treatment of pravastatin attenuates oxidative stress and protects osteoblast viability from indoxyl sulfate. Ther Apher Dial 2011, 15:151-155.
19. Nakamura K., Kusano K., Nakamura Y., et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002, 105:2867-2871.
20. Iwasaki Y., Kazama J.J., Yamato H., Fukagawa M. Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease. Bone 2011, 48:1260-1267.
21. Mitome J., Yamamoto H., Saito M., Yokoyama K., Marumo K., Hosoya T. Nonenzymatic cross-linking pentosidine increase in bone collagen and are associated with disorders of bone mineralization in dialysis patients. Calcif Tissue Int 2011, 88:521-529.
22. Kakuta T., Tanaka R., Hyodo T., et al. Sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 2011, 57:422-431.